ARTICLE | Management Tracks
Arbuckle becomes COO at Vertex
Plus: GlycoMimetics names Semerjian as King’s successor, plus updates from Pieris, Assembly and more
August 4, 2021 10:00 PM UTC
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) promoted Stuart Arbuckle from EVP and chief commercial offer to COO.
GlycoMimetics Inc. hired Harout Semerjian to succeed founding CEO Rachel King, who will remain with the glycobiology company as a board director and adviser. Semerjian most recently served as CEO of Immunomedics Inc. prior to its acquisition by Gilead Science Inc. (NASDAQ:GILD) in 2020...